PRGO as reported
Perrigo Company plc reported $4.18B of revenue over the trailing twelve months, −3.6% on the year before. 11 reported series are charted on this page, each one as filed.
$4.18B
Revenue, trailing twelve months · to Q1 2026 · −3.6% against the twelve months before
- Net Income
- −$1.82B
Net Income · +908% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $108M
Free Cash Flow · −41% year on year · trailing twelve months to Q1 2026
- Op Margin
- −36%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $4.18B | −3.6% | Q1 2026 |
| Net Income | −$1.82B | +908% | Q1 2026 |
| EPS | −$13.12 | +902% | Q1 2026 |
| Gross Margin | 34% | n/a | Q1 2026 |
| Op Margin | −36% | n/a | Q1 2026 |
| Net Margin | −42% | n/a | Q1 2026 |
| ROE | −31% | n/a | Q1 2026 |
| ROA | −10% | n/a | Q1 2026 |
| ROIC | −7.5% | n/a | Q1 2026 |
| Free Cash Flow | $108M | −41% | Q1 2026 |
| P/E | 28.7 | n/a | Q2 2020 · 23 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Perrigo Company plc (PRGO) - Revenue & ProfitRevenue & ProfitPerrigo Company plc (PRGO)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #28 of 28 by Smart Score